In MM cell lines with short MCL-1 half-life, which are expected to rely more on MCL1 transcription than on protein stabilization, no reduction in MCL-1 was seen following OA treatment (Fig. 4A, C). The gene discussed is MCL1; the disease is Miyoshi myopathy.